Abstract Number: 1279 • ACR Convergence 2020
Clinical Characteristics and Impact of the COVID-19 Pandemic in Systemic Lupus Erythematosus Patients in a Spanish Tertiary Hospital
Background/Purpose: Data about incidence, clinical characteristics and outcome of patients with Systemic Lupus Erythematosus (SLE) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease is…Abstract Number: 1295 • ACR Convergence 2020
Disease Activity and Mental Health in SLE Patients: A Cross-section Study with Self-Assessments Based on Smart System of Disease Management (SSDM) Mobile Tools
Background/Purpose: WHO survey showed that the prevalence of anxiety and depression in Chinese population and Chinese patients with chronic diseases were between 3.1% - 4.2%…Abstract Number: 1499 • ACR Convergence 2020
The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry
Background/Purpose: Several of the most commonly prescribed anti-rheumatic medications for women with rheumatic disease are known teratogens, posing a risk for pregnancy loss and birth…Abstract Number: 1621 • ACR Convergence 2020
Cervical Cancer Screening Among Women with Systemic Lupus Erythematosus or Prescribed Tumor Necrosis Alpha-inhibitors Who Receive Outpatient Rheumatology Care
Background/Purpose: Cervical cancer screening is important for women with systemic lupus erythematosus (SLE) and women prescribed TNF-alpha inhibitors (TNFi), as they have an increased risk…Abstract Number: 1681 • ACR Convergence 2020
Hemophagocytic Lymphohistiocytosis (HLH) Gene Variants in Childhood-onset SLE (cSLE) with Macrophage Activation Syndrome (MAS)
Background/Purpose: Familial Hemophagocytic lymphohistiocytosis (fHLH) is an autosomal recessive, hyper-inflammatory, life-threatening disease. Macrophage activation syndrome (MAS) is also known as secondary HLH due to the…Abstract Number: 1793 • ACR Convergence 2020
Safety of Obtaining Research Tissue During Clinically Indicated Kidney Biopsies: Data from the Lupus Accelerating Medicines Partnership
Background/Purpose: Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and affects ~60% of patients during the course of their disease, leading…Abstract Number: 1810 • ACR Convergence 2020
Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine
Background/Purpose: Mortality in patients with systemic lupus erythematosus (SLE) is significantly higher than in the general population. Treatment of SLE patients has improved, however, a…Abstract Number: 1827 • ACR Convergence 2020
Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials
Background/Purpose: Objectives of long-term SLE management are not only to reduce disease activity, but also to prevent flares and minimize exposure to oral corticosteroids (OCS),…Abstract Number: 1845 • ACR Convergence 2020
Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol: A Matched Case-Control Study
Background/Purpose: Targeting B-cells remains an attractive option in Lupus Nephritis (LN) despite the negative results of RCTs.Methods: Sixty patients with active LN were included in…Abstract Number: 0248 • ACR Convergence 2020
Assessment of Lupus Knowledge Through Creation of the Lupus Knowledge Assessment Test (LKAT)
Background/Purpose: Systemic lupus erythematosus (SLE) is an inherently complex disease to manage with heterogenous clinical manifestations and complicated medication regimens. The complexity of lupus self-management…Abstract Number: 0265 • ACR Convergence 2020
Evaluation of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus as a Measure of Systemic Lupus Erythematosus (SLE) Disease Activity from the Clinician and the Patient Perspective: Experience from an Italian Cohort
Background/Purpose: Multiple indices are available to measure disease activity in SLE patients, but are often considered too complex and time consuming for use in routine…Abstract Number: 0281 • ACR Convergence 2020
ANCA in SLE: Prevalence and Predictor Factors
Background/Purpose: SLE is a systemic autoimmune disease notable for the ability to affect nearly every tissue, and is associated with a breadth of auto-antibodies. Anti-neutrophilic…Abstract Number: 0299 • ACR Convergence 2020
The Minor Protective Allele at rs1876453 Is Associated with Increased Age of Onset of Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a clinically heterogenous autoimmune disease characterized by autoantibody- and complement-mediated inflammatory damage to multiple organ systems. We previously showed…Abstract Number: 0494 • ACR Convergence 2020
Genetic-epigenetic Interaction and the Relationship Between DNA Methylation Patterns and Disease Activity in a Longitudinal Cohort of Lupus Patients
Background/Purpose: Genetic factors and epigenetic dysregulation are implicated in the pathogenesis of lupus. We performed a longitudinal analysis of DNA methylation in lupus patients for…Abstract Number: 0612 • ACR Convergence 2020
Differences in 30-Day Rehospitalization Risk and Predictors by Age Group Among Patients with Lupus in Medicare
Background/Purpose: Although our recent research demonstrates that young adult Medicare beneficiaries (age 18-35) with lupus (SLE) have higher risk of 30-day rehospitalization, predictors specific to…
- « Previous Page
- 1
- …
- 116
- 117
- 118
- 119
- 120
- …
- 150
- Next Page »